Gracell Biotechnologies Inc expected to post a loss of 33  cents a share - Earnings Preview

Gracell Biotechnologies

11/03/2022 14:53

* Gracell Biotechnologies Inc  GRCL.OQ   GRCL.O  is expected
to show no change in quarterly revenue when it reports 
results on March 14. 
    * ​Refinitiv's mean analyst estimate for Gracell
Biotechnologies
Inc is for a loss of 33 cents per share. For the same quarter
last year, the company reported a loss of 16 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $33​, above​ its last closing price
of $2.88. ​​​

This summary was machine generated March 11 at 14:53 GMT.  All
figures in US dollars  unless otherwise stated